{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:02:15Z","timestamp":1790017335008,"version":"4.0.1"},"reference-count":28,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Form Res"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Rejoyn\n \n (CT-152) is a prescription digital therapeutic (DTx) adjunct to antidepressive medication authorized for patients with major depressive disorder. To better understand the patient benefit of DTx and other treatment modalities, current regulatory standards support the use of modern psychometric methods to interpret the clinical meaningfulness of treatment effects for patients. In the primary analysis of Rejoyn from the pivotal phase 3 Mirai trial (NCT04770285), Rejoyn showed a broad risk-to-benefit profile as demonstrated on multiple clinician- and patient-rated scales, including the primary efficacy outcome measure, the Montgomery-\u00c5sberg Depression Rating Scale (MADRS). These findings supported US Food and Drug Administration authorization of Rejoyn as a prescription DTx. However, the clinical relevance of these changes in the MADRS score is not immediately interpretable in clinical practice. Here, we present the results from several post hoc analyses of the Mirai trial data to support the interpretation of clinically meaningful treatment differences on clinician- and patient-reported change in depressive symptoms.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study had two main objectives: (1) establish threshold parameters that allow for clinically meaningful interpretation of the Mirai results in clinical practice, based on the clinical trial end points of change from baseline in depressive symptoms, and (2) apply this threshold in a responder and sensitivity analysis in the intent-to-treat (ITT) population (which is more frequently reported in pharmacological trials) to further support the interpretation of change in unblinded analysis of the Mirai results.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n For the Mirai meaningful within-patient change (MWPC) analysis, anchor-based methods were used to define an MWPC threshold by exploring the associations between the MADRS and the clinician-rated Clinical Global Impression-Severity Scale (CGI-S) and the patient-reported Patient Health Questionnaire 9-Item Scale (PHQ-9). Additional post hoc efficacy analyses (including that of responders) are reported for the ITT population.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Using the MWPC thresholds of 8 and 10 points (derived with the CGI-S and PHQ-9 as anchor measures, respectively), the distribution of MADRS responders favored the Rejoyn group over the sham group, and the Rejoyn group had 24%\u201047% higher odds of meaningful improvement on the MADRS. Post hoc ITT analyses also favored the Rejoyn group over the sham group for response rates and PHQ-9 and CGI-S score change from baseline.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Results are consistent with the primary findings of the Mirai trial, supporting the efficacy of Rejoyn as an adjunctive treatment to antidepressive medication monotherapy for adults with major depressive disorder. The MWPC analyses offered a measure of meaningful change on the MADRS, providing a framework of clinical meaningfulness for the Mirai trial findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/85037","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:25:06Z","timestamp":1777458306000},"page":"e85037-e85037","source":"Crossref","is-referenced-by-count":0,"title":["Supporting the Primary Outcomes of the Mirai Trial for the Adjunctive Digital Therapeutic Rejoyn (CT-152) in the Treatment of Major Depressive Disorder: Meaningful Change Analysis in the Montgomery-\u00c5sberg Depression Rating Scale"],"prefix":"10.2196","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-1549","authenticated-orcid":false,"given":"Stacie","family":"Hudgens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-5644","authenticated-orcid":false,"given":"Intan","family":"Purnajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0584-6227","authenticated-orcid":false,"given":"Lysbeth","family":"Floden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-7405","authenticated-orcid":false,"given":"Steve","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3625-962X","authenticated-orcid":false,"given":"Jessica","family":"Ash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5780-2559","authenticated-orcid":false,"given":"Brian","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4260-7172","authenticated-orcid":false,"given":"Austin","family":"Speier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-7752","authenticated-orcid":false,"given":"Ainslie","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"1","key":"R1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JCP.0000000000001638","article-title":"Early response to antidepressant medications in adults with major depressive disorder: a naturalistic study and odds of remission at 14 weeks","volume":"43","author":"Belanger","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"R2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.7326\/0003-4819-155-11-201112060-00009","article-title":"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis","volume":"155","author":"Gartlehner","journal-title":"Ann Intern Med"},{"issue":"11","key":"R3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","journal-title":"Am J Psychiatry"},{"issue":"6 Suppl 3","key":"R4","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.amepre.2018.01.004","article-title":"Geographic variation in the supply of selected behavioral health providers","volume":"54","author":"Andrilla","journal-title":"Am J Prev Med"},{"issue":"1","key":"R5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1176\/appi.focus.20190028","article-title":"Challenges and opportunities to meet the mental health needs of underserved and disenfranchised populations in the United States","volume":"18","author":"Mongelli","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"2","key":"R6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/09638237.2019.1644494","article-title":"The association of depression stigma with barriers to seeking mental health care: a cross-sectional analysis","volume":"29","author":"Arnaez","journal-title":"J Ment Health"},{"key":"R7","unstructured":"Otsuka and Click Therapeutics announce the U.S. Food and Drug Administration (FDA) clearance of Rejoyn\u2122, the first prescription digital therapeutic authorized for the adjunctive treatment of major depressive disorder (MDD) symptoms. Otsuka America Pharmaceutical Inc. 2024. URL: https:\/\/otsuka-us.com\/news\/rejoyn-fda-authorized [Accessed 22-09-2026]"},{"key":"R8","unstructured":"Otsuka America Pharmaceutical Inc. Clinician brief summary. Rejoyn. 2024. URL: https:\/\/www.rejoynhcp.com\/Clinician-Brief-Summary.pdf [Accessed 22-08-2024]"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.119409","article-title":"A digital therapeutic (CT-152) as adjunct to antidepressant medication: a phase 3 randomized controlled trial (the Mirai study)","volume":"388","author":"Rothman","journal-title":"J Affect Disord"},{"key":"R10","unstructured":"Clinical outcome assessment (COA) Compendium. US Food and Drug Administration. 2021. URL: https:\/\/www.fda.gov\/drugs\/development-resources\/clinical-outcome-assessment-compendium [Accessed 22-08-2024]"},{"key":"R11","unstructured":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. US Food and Drug Administration. 2024. URL: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical [Accessed 22-08-2024]"},{"key":"R12","unstructured":"Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. US Food and Drug Administration. 2022. URL: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome [Accessed 22-08-2024]"},{"key":"R13","unstructured":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. US Food and Drug Administration. 2023. URL: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory [Accessed 22-08-2023]"},{"issue":"2","key":"R14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","article-title":"Interpreting patient-reported outcome results: US FDA guidance and emerging methods","volume":"11","author":"McLeod","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.066","article-title":"Meaningful change in depression symptoms assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-\u00c5sberg Depression Rating Scale (MADRS) among patients with treatment resistant depression in two, randomized, double-blind, active-controlled trials of esketamine nasal spray combined with a new oral antidepressant","volume":"281","author":"Hudgens","journal-title":"J Affect Disord"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores","volume":"27","author":"Coon","journal-title":"Qual Life Res"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.2196\/56960","article-title":"Evaluating the efficacy of a digital therapeutic (CT-152) as an adjunct to antidepressant treatment in adults with major depressive disorder: protocol for the MIRAI remote study","volume":"13","author":"Rothman","journal-title":"JMIR Res Protoc"},{"issue":"3","key":"R18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/mpr.1388","article-title":"The structure of the Montgomery-\u00c5sberg depression rating scale over the course of treatment for depression","volume":"22","author":"Quilty","journal-title":"Int J Methods Psychiatr Res"},{"issue":"7","key":"R19","first-page":"28","volume":"4","author":"Busner","journal-title":"Psychiatry (Edgmont)"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.747139","article-title":"The Patient Health Questionnaire-9 vs. the Hamilton Rating Scale for depression in assessing major depressive disorder","volume":"12","author":"Ma","journal-title":"Front Psychiatry"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Jacob C . Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1988. [doi: 10.4324\/9780203771587]","DOI":"10.4324\/9780203771587"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/acps.13260","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression","volume":"143","author":"Turkoz","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"R23","doi-asserted-by":"publisher","first-page":"32025826","DOI":"10.1007\/s11920-020-1134-9","article-title":"Apps for depression: are they ready to work?","volume":"22","author":"Porras-Segovia","journal-title":"Curr Psychiatry Rep"},{"issue":"5","key":"R24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1176\/appi.ajp.2019.19090905","article-title":"Examining the reach of smartphone apps for depression and anxiety","volume":"177","author":"Wasil","journal-title":"Am J Psychiatry"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-019-0188-8","article-title":"Standalone smartphone apps for mental health\u2014a systematic review and meta-analysis","volume":"2","author":"Weisel","journal-title":"NPJ Digit Med"},{"issue":"3","key":"R26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/wps.20883","article-title":"The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality","volume":"20","author":"Torous","journal-title":"World Psychiatry"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.12.041","article-title":"What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies","volume":"210","author":"Leucht","journal-title":"J Affect Disord"},{"key":"R28","unstructured":"Otsuka Clinical Trial Transparency. Otsuka America Pharmaceutical, Inc. URL: https:\/\/clinical-trials.otsuka.com\/ [Accessed 11-09-2026]"}],"container-title":["JMIR Formative Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:23:46Z","timestamp":1790015026000},"score":1,"resource":{"primary":{"URL":"https:\/\/formative.jmir.org\/2026\/1\/e85037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2196\/85037","relation":{},"ISSN":["2561-326X"],"issn-type":[{"value":"2561-326X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"v10i1e85037"}}